Practical Strategies for Managing Bleeding Risk with NOACs: The Role of Reversal Agents

J W Eikelboom

PROGRAMME INFORMATION: This activity is supported by educational grants from Boehringer Ingelheim, and Bristol-Myers Squibb and Pfizer.

PeerVoice activities are designed to fill the unmet needs of the medical community by reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. The preparation of PeerVoice activities is supported by written agreements that clearly stipulate and enforce the editorial independence of PeerVoice and the faculty presenters.

The faculty may discuss unapproved products or uses of these products in certain jurisdictions. Faculty presenters have been advised to disclose any reference to an unlabelled or unapproved use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our activities. No responsibility is taken for errors or omissions.

For approved prescribing information, please consult the manufacturer's product monograph.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerVoice or any of its supporters.

Visit the site here